

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **May 7, 2015**

**PLASMATECH BIOPHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**0-9314**  
(Commission File Number)

**83-0221517**  
(I.R.S. Employer Identification No.)

**4848 Lemmon Avenue, Suite 517**  
**Dallas, TX 75219**  
(Address of principal executive offices) (Zip Code)

**(214) 905-5100**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The annual meeting of stockholders of PlasmaTech Biopharmaceutical, Inc. (the "Company") was held on May 7, 2015. The following matters were acted upon:

1. ELECTION OF DIRECTORS

Steven H. Rouhandeh was elected to serve as director of the Company until his successor is duly elected and qualified. The results of the election of director is as follows:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Steven H. Rouhandeh	16,361,077	7,390	1,011,886

Stephen B. Howell was elected to serve as director of the Company until his successor is duly elected and qualified. The results of the election of director is as follows:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Stephen B. Howell	16,361,591	6,876	1,011,886

2. APPROVAL OF THE 2015 EQUITY INCENTIVE PLAN.

Approval of the 2015 Equity Incentive Plan was approved by the following votes:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
16,306,350	59,519	2,598	1,011,886

3. RATIFICATION OF APPOINTMENT OF WHITLEY PENN LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2015.

Ratification of the appointment of Whitley Penn LLP as the independent registered public accounting firm of the Company was approved by the following votes:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
17,276,909	97,925	5,519	0

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PlasmaTech Biopharmaceuticals, Inc.  
(Registrant)

By: /s/ Stephen B. Thompson  
Stephen B. Thompson  
Vice President Finance  
Chief Accounting Officer

Dated May 8, 2015

---